US loss of exclusivity · Immunology
Nucala
GSK
2029
US biosimilars from
2025
Today: 2026
2037
2025 worldwide sales
≈$2.6B
Date basis
Patent-expiry estimate
US biosimilars
In clinical trials
Pharma Patent Cliff
by readouts.io
Data checked 8 October 2026 ·
Full Nucala timeline →